Connor E. Dunn

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer

Adrienne G. Waks, Ofir Cohen, Bose Kochupurakkal et al. · Annals of Oncology · 2020 · 156 citations · Full text

Medicine, Cancer Biology, Oncology +17

The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition

Kalindi Parmar, Bose Kochupurakkal, Jean‐Bernard Lazaro et al. · Clinical Cancer Research · 2019 · 147 citations

Medicine, Oncology, Pharmacology +17

Cooperation of the ATM and Fanconi Anemia/BRCA Pathways in Double-Strand Break End Resection

Muyan Cai, Connor E. Dunn, Wenxu Chen et al. · Cell Reports · 2020 · 84 citations · Full text

Life Sciences, Genetics, Oncology +17

CHK1 Inhibitor Blocks Phosphorylation of FAM122A and Promotes Replication Stress

Feng Li, David Kozono, Peter Deraska et al. · Molecular Cell · 2020 · 55 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +12

Substratum stiffness signals through integrin-linked kinase and β1-integrin to regulate midbody proteins and abscission during EMT

Emann Rabie, Sherry X. Zhang, Connor E. Dunn et al. · Molecular Biology of the Cell · 2021 · 28 citations · Full text

Life Sciences, Cancer Biology, Cell Biology +17